ID: ALA247262

Max Phase: Preclinical

Molecular Formula: C21H32BrNO5

Molecular Weight: 458.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@H](CCC(=O)O)NC(=O)/C=C/C(C)(C)C/C=C(\C)CC/C=C(\C)Br

Standard InChI:  InChI=1S/C21H32BrNO5/c1-15(7-6-8-16(2)22)11-13-21(3,4)14-12-18(24)23-17(20(27)28-5)9-10-19(25)26/h8,11-12,14,17H,6-7,9-10,13H2,1-5H3,(H,23,24)(H,25,26)/b14-12+,15-11+,16-8+/t17-/m0/s1

Standard InChI Key:  QQEZKHUUKICZDA-AKULKUFQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.39

Molecular Weight (Monoisotopic): 457.1464

AlogP: 4.51

#Rotatable Bonds: 12

Polar Surface Area: 92.70

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.93

CX Basic pKa:

CX LogP: 4.01

CX LogD: 0.81

Aromatic Rings: 0

Heavy Atoms: 28

QED Weighted: 0.26

Np Likeness Score: 0.95

References

1. Kitayama T, Iwabuchi R, Minagawa S, Sawada S, Okumura R, Hoshino K, Cappiello J, Utsumi R..  (2007)  Synthesis of a novel inhibitor against MRSA and VRE: preparation from zerumbone ring opening material showing histidine-kinase inhibition.,  17  (4): [PMID:17157007] [10.1016/j.bmcl.2006.11.015]

Source

Source(1):

• Scientific Literature